




Supplementary figure 1: Pie chart showing the repartition of protein classes of potential druggable candidates for NSC765690 and NSC765599.




Supplementary figure 2: Docking profiles of NSC765690 with CDK2, CDK4, and CDK6. (A) The three-dimensional (3D) structures of ligand-receptor interactions of NSC765690 with CDK2, -4, and -6. (B) The surface representations of the active-site flap of the CDK2/4/6 complex with NSC765690 in the binding pocket.




Supplementary figure 3: Docking profiles of NSC765599 with CDK2, CDK4, and CDK6. (A) The three-dimensional (3D) structures of ligand-receptor interactions of NSC765599 with CDK2, -4, and -6. (B) The surface representations of the active-site flap of the CDK2/4/6 complex with NSC765599 in the binding pocket.




Supplementary figure 4: Docking profiles of palbociclib with CDK2, CDK4, and CDK6. (A) The three-dimensional (3D) structures of ligand-receptor interactions of palbociclib with CDK2, -4, and -6. (B) The surface representations of the active-site flap of the CDK2/4/6 complex with palbociclib in the binding pocket.



Supplementary figure 5: Comparative docking profiles of STAT3 with NSC765599, NSC765690, and SH-4-54 (a known STAT3 inhibitor). (A) The shows 3D structures of ligand-receptor interactions. (B) The show the surface representations of active-site flaps of the STAT3 complex with ligands in the binding pocket.



Supplementary figure 6: BOILED-Egg model of brain or intestinal estimated permeation of NSC765599 and NSC765690



Supplementary Figure 7: Bioavailability Radar showing suitable physicochemical spaces of the oral bioavailability of NSC765690 and NSC765599. The pink area represents the optimal range for each property. LIPO, lipophilicity; POLAR, polarity; INSOLU, insolubility; INSATU, unsaturation; FLEX, flexibility; Fraction Csp3, fraction of carbons in sp³ hybridization.